ArticleNeurogenetics2025
Missense variants in PKAN: insights from a multi-patient genetic analysis.
Article in Neurogenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Pantothenate kinase-associated neurodegeneration (PKAN) is a common subtype of neurodegeneration with brain iron accumulation (NBIA), caused by biallelic variants in the PANK2 gene. In this study, we investigated five unrelated patients clinically suspected of PKAN (four atypical, one classical) using next-generation sequencing followed by Sanger confirmation and segregation analysis where appropriate. We identified five distinct missense variants, including one novel association, all occurring in biallelic states. Notably, two patients carried the same homozygous variant (ENST00000610179.7:c.503G > T), previously associated with atypical PKAN, which may suggest either an elevated local carrier frequency or an unrecognized founder effect. The ENST00000610179.7:c.1253C>T; p.(Thr418Met) variant, identified in a patient with late-onset PKAN, has previously been reported in both classical and atypical forms of the disease, suggesting that residual enzyme activity may contribute to the observed phenotypic variability. To evaluate the impact of missense variants, we employed DynaMut2 and AlphaMissense. Two variants were predicted to be structurally destabilizing and pathogenic, while others showed neutral or conflicting predictions. Our findings highlight the complexity of interpreting missense variants in PKAN and support the utility of combining in silico predictions with detailed genotype–phenotype correlations. Although no consistent pattern was observed across all prediction tools and clinical outcomes, this study contributes to the expanding mutational spectrum of PANK2 and emphasizes the need for further functional validation to improve diagnostic accuracy in NBIA disorders.
Indexed as
Identifiers
41288799What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.